Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry

Carmelo Giaccotto, Rexford Santerre () and John A Vernon

Journal of Law and Economics, 2005, vol. 48, issue 1, 195-214

Abstract: This paper argues theoretically and shows empirically that pharmaceutical R&D spending increases with real drug prices, after holding constant other determinants of research and development (R&D). Specifically, an estimated elasticity suggests that a 10 percent increase in the growth of real drug prices is associated with nearly a 6 percent increase in the growth of R&D intensity. Simulations that are based on our multiple-regression model indicate that the capitalized value of pharmaceutical R&D spending would have been about 30 percent lower if the federal government had limited the rate of growth in drug price increases to the rate of growth in the general consumer price index during the period 1980-2001. Moreover, the results suggest that a drug price control regime would have resulted in 330--65 fewer new drugs, representing over one-third of all actual new drug launches brought to the global market during that time period.

Date: 2005
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (56)

Downloads: (external link)
http://dx.doi.org/10.1086/426882 (application/pdf)
Access to the online full text or PDF requires a subscription.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ucp:jlawec:y:2005:v:48:i:1:p:195-214

Access Statistics for this article

More articles in Journal of Law and Economics from University of Chicago Press
Bibliographic data for series maintained by Journals Division ().